Literature DB >> 32607817

The Developmental Trajectory of Cancer-Related Cognitive Impairment in Breast Cancer Patients: A Systematic Review of Longitudinal Neuroimaging Studies.

Helena Sousa1,2, Susana Almeida2,3, João Bessa2,4,5, M Graça Pereira6,7.   

Abstract

This systematic review explored the neurobiological mechanisms underlying the clinical time course of cancer-related cognitive impairment (CRCI) in breast cancer patients through the review of longitudinal neuroimaging studies. Before chemotherapy, results reported no evidence for neuropsychological, structural (gray matter) and brain perfusion changes. However, functional brain alterations were evident and revealed a frontoparietal hyperactivation during working memory tasks. Fatigue and number of days since surgery were the two suggested confounding factors. Acutely after chemotherapy, this review found no evidence for neuropsychological changes while suggesting a pattern of frontal structural, perfusion and functional brain abnormalities. These findings seemed to be dependent on age, menopausal status at baseline, and fMRI task performed. Years after chemotherapy, results revealed evidence of partial neuropsychological, structural, and functional brain recovery. Regarding brain abnormality, this review suggested that it may begin quite early in the disease course, be more prominent shortly after chemotherapy and partially recover over time. Several hypotheses underlying these changes were discussed. The present review also provided important information for developing a time-specific treatment and prevention strategies and for the consideration of functional neuroimaging as a relevant tool for CRCI diagnosis, clinical monitoring, and intervention studies. The findings also suggested the need to implement studies with longitudinal designs, including a pre-treatment assessment, since cross-sectional studies were not able to detect this pattern of recovery over time, supporting only the theory of brain abnormalities, in breast cancer survivors.

Entities:  

Keywords:  Breast cancer; Cancer-related cognitive impairment; Cognition; MRI; Neuroimaging; fMRI

Mesh:

Year:  2020        PMID: 32607817     DOI: 10.1007/s11065-020-09441-9

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  13 in total

Review 1.  Neuropsychological Interventions for Cancer-Related Cognitive Impairment: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Andy S K Cheng; Xiaoming Wang; Niu Niu; Minyu Liang; Yingchun Zeng
Journal:  Neuropsychol Rev       Date:  2022-01-29       Impact factor: 7.444

2.  Dynamic functional network connectivity reveals the brain functional alterations in lung cancer patients after chemotherapy.

Authors:  Lanyue Hu; Shaohua Ding; Yujie Zhang; Jia You; Song'an Shang; Peng Wang; Xindao Yin; Wenqing Xia; Yu-Chen Chen
Journal:  Brain Imaging Behav       Date:  2021-10-31       Impact factor: 3.978

3.  Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy.

Authors:  Brenna C McDonald; Kathleen Van Dyk; Jeanne S Mandelblatt; Andrew J Saykin; Rachael L Deardorff; Jessica N Bailey; Wanting Zhai; Judith E Carroll; James C Root; Tim A Ahles
Journal:  Breast Cancer Res Treat       Date:  2022-04-27       Impact factor: 4.624

4.  Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer.

Authors:  Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

5.  Altered Regional Brain Glucose Metabolism in Diffuse Large B-Cell Lymphoma Patients Treated With Cyclophosphamide, Epirubicin, Vincristine, and Prednisone: An Fluorodeoxyglucose Positron Emission Tomography Study of 205 Cases.

Authors:  Yuxiao Hu; Qin Zhang; Can Cui; Yun Zhang
Journal:  Front Neurosci       Date:  2022-06-15       Impact factor: 5.152

Review 6.  Mapping cognitive deficits in cancer patients after chemotherapy: An Activation Likelihood Estimation meta-analysis of task-related fMRI studies.

Authors:  Jacqueline B Saward; Elizabeth G Ellis; Annalee L Cobden; Karen Caeyenberghs
Journal:  Brain Imaging Behav       Date:  2022-04-02       Impact factor: 3.224

7.  Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer Based on Functional Assessment and NIRS Analysis.

Authors:  Noelia Durán-Gómez; Casimiro Fermín López-Jurado; Marta Nadal-Delgado; Demetrio Pérez-Civantos; Jorge Guerrero-Martín; Macarena C Cáceres
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

8.  Cross-Sectional Characterization of Local Brain Network Connectivity Pre and Post Breast Cancer Treatment and Distinct Association With Subjective Cognitive and Psychological Function.

Authors:  Shelli R Kesler; Tien Tang; Ashley M Henneghan; Michelle Wright; M Waleed Gaber; Oxana Palesh
Journal:  Front Neurol       Date:  2021-10-29       Impact factor: 4.003

Review 9.  Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy.

Authors:  Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Steven M Paul; Christine Ritchie; Kristina Lindemann; Ingvild Vistad; Claudia Rodríguez-Aranda; Christine Miaskowski
Journal:  Nurs Open       Date:  2021-12-08

Review 10.  A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue.

Authors:  Jan Petr; Louise Hogeboom; Pavel Nikulin; Evita Wiegers; Gwen Schroyen; Jesper Kallehauge; Marek Chmelík; Patricia Clement; Ruben E Nechifor; Liviu-Andrei Fodor; Philip C De Witt Hamer; Frederik Barkhof; Cyril Pernet; Maarten Lequin; Sabine Deprez; Radim Jančálek; Henk J M M Mutsaerts; Francesca B Pizzini; Kyrre E Emblem; Vera C Keil
Journal:  MAGMA       Date:  2021-12-17       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.